AR035611A1 - 2 -azetidinonas sustituidas con azucares, composicion farmaceutica, un kit, uso de dichos compuestos para la fabricacion de medicamentos utiles como agentes hipocolesterolemicos. - Google Patents
2 -azetidinonas sustituidas con azucares, composicion farmaceutica, un kit, uso de dichos compuestos para la fabricacion de medicamentos utiles como agentes hipocolesterolemicos.Info
- Publication number
- AR035611A1 AR035611A1 ARP010105837A ARP010105837A AR035611A1 AR 035611 A1 AR035611 A1 AR 035611A1 AR P010105837 A ARP010105837 A AR P010105837A AR P010105837 A ARP010105837 A AR P010105837A AR 035611 A1 AR035611 A1 AR 035611A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- independently selected
- substituted
- aryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Chemical group 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title 1
- 150000008163 sugars Chemical group 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 14
- 125000003118 aryl group Chemical group 0.000 abstract 7
- -1 -OH Inorganic materials 0.000 abstract 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 abstract 3
- 235000012000 cholesterol Nutrition 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000002541 furyl group Chemical group 0.000 abstract 2
- 125000002883 imidazolyl group Chemical group 0.000 abstract 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 abstract 2
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 2
- 125000002757 morpholinyl group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000003386 piperidinyl group Chemical group 0.000 abstract 2
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 2
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000000335 thiazolyl group Chemical group 0.000 abstract 2
- 125000001544 thienyl group Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 abstract 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000003638 chemical reducing agent Substances 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000001786 isothiazolyl group Chemical group 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003003 spiro group Chemical group 0.000 abstract 1
- 125000001113 thiadiazolyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
2-Azetidinonas sustituidas con azúcares, que comprenden un compuesto representado por la fórmula estructural (1), o una sal farmacéuticamente aceptable del mismo, en donde R26 se selecciona entre el grupo que consiste de: OH, OCH3, flúor y cloro; R1 se selecciona entre el grupo que consiste de H, compuestos de fórmulas (2), (3), (4) ó (5), -SO3H, aminoácidos naturales y no naturales; R, Ra y Rb se seleccionan de manera independiente entre el grupo que consiste de H, -OH, halógeno, -NH2, azido, alcoxi C1-6alcoxi C1-6 o -W-R30; W se selecciona independientemente entre el grupo que consiste de -NH-C(O)-, -O-C(O)-, -O-C(O)-N(R31)-, -NH-C(O)-N(R31)- y -O-C(S)-N(R31)-; R2 y R6 se seleccionan de manera independiente entre el grupo que consiste de H, alquilo C1-6, arilo y aril alquilo C1-6; R3, R4, R5, R7, R3a y R4a se seleccionan de manera independiente entre el grupo que consiste de H, alquilo C1-6, aril alquilo C1-6, -C(O)alquilo C1-6 y -C(O)arilo; R30 se selecciona de manera independiente entre el grupo que consiste de TR32-sustituido, TR32-sustituido-alquilo C1-6, alquenilo C2-4R32-sustituido, alquilo C1-6R32-sustituido, cicloalquilo C3-7R32-sustituido y cicloalquilo C3-7alquilo C1-6R32-sustituido; R31 se selecciona de manera independiente entre el grupo que consiste de H y alquilo C1-4; T se selecciona de manera independiente entre el grupo que consiste de fenilo, furilo, tienilo, pirrolilo, oxazolilo, isoxazolilo, tiazolilo, isotiazolilo, benzotiazolilo, tiadiazolilo, pirazolilo, imidazolilo y piridilo; R32 se selecciona de manera independiente entre 1-3 sustituyentes seleccionados independientemente entre el grupo que consiste de H, halógeno, alquilo C1-4, -OH, fenoxi, -CF3, -NO2, alcoxi C1-4, metilendioxi, oxo, alquilsulfanilo C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, -N(CH3)2, -C(O)-NHalquilo C1-4, -C(O)-N(alquilo C1-4)2, -C(O)-alquilo C1-4, -C(O)-alcoxi C1-4 y pirrolidinilcarbonilo; o R32 es un enlace covalente y R31, el nitrógeno al cual está unido y R32 forman un grupo pirrolidinilo, piperidinilo, N-metil-piperazinilo, indolinilo o morfolinilo, o un grupo piperidinilo, N-metilpiperazinilo, indolinilo, morfolinilo, o pirrolidinilo alcoxicarbonilo C1-4-sustituido; Ar1 es arilo o ariloR10-sustituido; Ar2 es arilo o ariloR11-sustituido; Q es -(CH2)q-, en donde q es 2-6, o con el carbono de anillo de la posición 3 de la azetidinona, forma el grupo espiro (6); R12 es >CH-, >C(alquilo C1-6)-, >CF-, >C(OH), >C(C6H4-R23)-, >N-, ó lN+O-; R13 y R14 se seleccionan de manera independiente entre el grupo que consiste de -CH2-, -CH(alquilo C1-6)-, -C(di-alquilo C1-6), -CH=CH- y -C(alquilo C1-6)=CH-; o R12 junto con un R13 adyacente, o R12 junto con un R14 adyacente, forman un grupo -CH=CH- o un grupo -CH=C(alquilo C1-6)-; a y b son independientemente 0, 1, 2, ó 3, siempre y cuando no son ambos cero, siempre que cuando R13 es -CH=CH- o -C(alquilo C1-6)=CH-, a es 1; siempre que cuando R14 es -CH=CH- o -C(alquilo C1-6)=CH-, b es 1; siempre que cuando a es 2 ó 3, los R13 pueden ser iguales o diferentes; y siempre que cuando b es 2 ó 3, los R14 pueden ser iguales o diferentes; R10 y R11 se seleccionan de manera independiente entre el grupo que consiste de 1-3 sustituyentes seleccionados independientemente entre el grupo que consiste de alquilo C1-6, -OR19, -O(CO)R19, -O(CO)OR21, -O(CH2)1-5OR19, -O(CO)NR19R20, -NR19R20, -NR19(CO)R20, -NR19(CO)OR21, -NR19(CO)NR20R25, -NR19SO2R21, -COOR19, -CONR19R20, -COR19, -SO2NR19R20, -S(O)0-2R21, -O(CH2)1-10COOR19, -O(CH2)1-10CONR19R20, -(alquileno C1-6)-COOR19, -CH=CH-COOR19, -CF3, -CN, -NO2 y halógeno; Ar también puede ser piridilo, isoxazolilo, furanilo, pirrolilo, tienilo, imidazolilo, pirazolilo, tiazolilo, pirazinilo, pirimidinilo o piridazinilo; R19 y R20 se seleccionan de manera independiente entre el grupo que consiste de H, alquilo C1-6, arilo y alquilo C1-6arilo-sustituido; R21 es alquilo C1-6, arilo o ariloR24-sustituido; R22 es H, alquilo C1-6, aril alquilo C1-6, -C(O)R19 o -COOR19; R23 y R24 son independientemente 1-3 grupos seleccionados de manera independiente entre el grupo que consiste de H, alquilo C1-6, alcoxi C1-6, -COOH, NO2, -NR19R20, -OH y halógeno; y R25 es H, -OH o alcoxi C1-6; composiciones farmacéuticas que contienen los mismos, y la combinación de un agente reductor del colesterol de 2-azetidinona sustituido con azúcar, y un inhibidor de la biosíntesis de colesterol, para el tratamiento y prevención de arteriosclerosis. Uso de dichos compuestos de fórmula (1) para la fabricación de medicamentos para disminuir el colesterol por medio de la administración de dicho compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25687500P | 2000-12-20 | 2000-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035611A1 true AR035611A1 (es) | 2004-06-16 |
Family
ID=22973953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010105837A AR035611A1 (es) | 2000-12-20 | 2001-12-17 | 2 -azetidinonas sustituidas con azucares, composicion farmaceutica, un kit, uso de dichos compuestos para la fabricacion de medicamentos utiles como agentes hipocolesterolemicos. |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US20020137690A1 (es) |
| EP (1) | EP1347987B1 (es) |
| JP (2) | JP4351842B2 (es) |
| KR (1) | KR100883461B1 (es) |
| CN (1) | CN100475829C (es) |
| AR (1) | AR035611A1 (es) |
| AT (2) | ATE279425T1 (es) |
| AU (2) | AU2002231049B2 (es) |
| BR (1) | BR0116212A (es) |
| CA (1) | CA2432798C (es) |
| CY (1) | CY1106912T1 (es) |
| CZ (1) | CZ302193B6 (es) |
| DE (2) | DE60129863T2 (es) |
| DK (2) | DK1347987T3 (es) |
| EC (1) | ECSP034659A (es) |
| ES (2) | ES2287826T3 (es) |
| GE (1) | GEP20053548B (es) |
| HU (1) | HUP0302269A3 (es) |
| IL (1) | IL155771A0 (es) |
| MA (1) | MA26975A1 (es) |
| MX (1) | MXPA03005671A (es) |
| MY (1) | MY129148A (es) |
| NO (2) | NO326981B1 (es) |
| NZ (1) | NZ525722A (es) |
| PE (1) | PE20020718A1 (es) |
| PL (1) | PL208242B1 (es) |
| PT (2) | PT1593670E (es) |
| RU (1) | RU2297422C2 (es) |
| SI (2) | SI1347987T1 (es) |
| SK (1) | SK286703B6 (es) |
| TR (1) | TR200402758T4 (es) |
| TW (1) | TWI316942B (es) |
| WO (1) | WO2002050090A1 (es) |
| ZA (1) | ZA200303694B (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| SI1413331T1 (sl) | 2001-01-26 | 2008-02-29 | Schering Corp | Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije |
| RS50406B (sr) | 2001-01-26 | 2009-12-31 | Schering Corporation, | Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije |
| UA75644C2 (en) | 2001-03-28 | 2006-05-15 | Schering Corp | Enantioselective synthesis of azetidinone intermediate compounds |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| MXPA04002573A (es) | 2001-09-21 | 2004-06-18 | Schering Corp | Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol. |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
| AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
| EP1562582A1 (en) | 2002-11-06 | 2005-08-17 | Schering Corporation | Cholesterol absorption inhibitors for the treatment of demyelination |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| JP4589919B2 (ja) | 2003-03-07 | 2010-12-01 | シェーリング コーポレイション | 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用 |
| ES2311806T3 (es) | 2003-03-07 | 2009-02-16 | Schering Corporation | Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia. |
| US7192944B2 (en) | 2003-03-07 | 2007-03-20 | Schering Corp. | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| JP2005015434A (ja) | 2003-06-27 | 2005-01-20 | Kotobuki Seiyaku Kk | 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤 |
| EP1522541A1 (en) * | 2003-10-07 | 2005-04-13 | Lipideon Biotechnology AG | Novel hypocholesterolemic compounds |
| EP1918000A2 (en) | 2003-11-05 | 2008-05-07 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
| ATE485267T1 (de) * | 2003-12-23 | 2010-11-15 | Astrazeneca Ab | Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung |
| JP2007516287A (ja) | 2003-12-23 | 2007-06-21 | メルク エンド カムパニー インコーポレーテッド | 抗高コレステロール血症化合物 |
| GB0329778D0 (en) * | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
| MX2007003732A (es) * | 2004-09-29 | 2007-04-23 | Schering Corp | Combinaciones de azetidononas sustituidas y antagonistas de receptor de canabinoide 1. |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| AR054482A1 (es) * | 2005-06-22 | 2007-06-27 | Astrazeneca Ab | Derivados de azetidinona para el tratamiento de hiperlipidemias |
| SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
| RU2008136765A (ru) * | 2006-03-06 | 2010-04-20 | Тева Фармасьютикл Индастриес Лтд. (Il) | Композиции эзетимиба |
| AR060623A1 (es) | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
| CN101652377A (zh) * | 2007-04-02 | 2010-02-17 | 泰拉科斯有限公司 | 苄基化糖苷衍生物及其用法 |
| WO2010075068A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
| EP2379562A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
| ES2487540T3 (es) * | 2009-02-11 | 2014-08-21 | Dow Agrosciences Llc | Composiciones plaguicidas |
| WO2010100255A1 (en) | 2009-03-06 | 2010-09-10 | Lipideon Biotechnology Ag | Pharmaceutical hypocholesterolemic compositions |
| EP2414529A2 (en) | 2009-04-01 | 2012-02-08 | Matrix Laboratories Ltd | Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe |
| CN101993403B (zh) | 2009-08-11 | 2012-07-11 | 浙江海正药业股份有限公司 | 氮杂环丁酮类化合物及医药应用 |
| KR101102749B1 (ko) * | 2009-11-30 | 2012-01-05 | 최길용 | 곱셈 학습기 |
| KR20150079373A (ko) | 2013-12-30 | 2015-07-08 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 |
| CN105055404B (zh) * | 2015-08-19 | 2017-07-18 | 四川大学 | Hmgcs2抑制剂在制备治疗可卡因成瘾的药物中的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3595B (en) * | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5627176A (en) * | 1994-03-25 | 1997-05-06 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5633246A (en) * | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| MY114803A (en) * | 1995-10-31 | 2003-01-31 | Schering Corp | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| US5756470A (en) * | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| AUPQ342599A0 (en) * | 1999-10-14 | 1999-11-04 | University Of Melbourne, The | Conjugates and uses thereof |
-
2001
- 2001-12-17 CZ CZ20031674A patent/CZ302193B6/cs not_active IP Right Cessation
- 2001-12-17 CA CA002432798A patent/CA2432798C/en not_active Expired - Fee Related
- 2001-12-17 SI SI200130228T patent/SI1347987T1/xx unknown
- 2001-12-17 ES ES05004699T patent/ES2287826T3/es not_active Expired - Lifetime
- 2001-12-17 SK SK770-2003A patent/SK286703B6/sk not_active IP Right Cessation
- 2001-12-17 EP EP01991315A patent/EP1347987B1/en not_active Expired - Lifetime
- 2001-12-17 BR BR0116212-8A patent/BR0116212A/pt active Search and Examination
- 2001-12-17 WO PCT/US2001/049127 patent/WO2002050090A1/en not_active Ceased
- 2001-12-17 DK DK01991315T patent/DK1347987T3/da active
- 2001-12-17 PL PL363237A patent/PL208242B1/pl not_active IP Right Cessation
- 2001-12-17 PT PT05004699T patent/PT1593670E/pt unknown
- 2001-12-17 DE DE60129863T patent/DE60129863T2/de not_active Expired - Lifetime
- 2001-12-17 AT AT01991315T patent/ATE279425T1/de active
- 2001-12-17 KR KR1020037007778A patent/KR100883461B1/ko not_active Expired - Fee Related
- 2001-12-17 AU AU2002231049A patent/AU2002231049B2/en not_active Ceased
- 2001-12-17 AR ARP010105837A patent/AR035611A1/es not_active Application Discontinuation
- 2001-12-17 NZ NZ525722A patent/NZ525722A/en not_active IP Right Cessation
- 2001-12-17 AT AT05004699T patent/ATE369334T1/de active
- 2001-12-17 US US10/023,295 patent/US20020137690A1/en not_active Abandoned
- 2001-12-17 HU HU0302269A patent/HUP0302269A3/hu unknown
- 2001-12-17 RU RU2003122520/04A patent/RU2297422C2/ru not_active IP Right Cessation
- 2001-12-17 AU AU3104902A patent/AU3104902A/xx active Pending
- 2001-12-17 PT PT01991315T patent/PT1347987E/pt unknown
- 2001-12-17 MX MXPA03005671A patent/MXPA03005671A/es active IP Right Grant
- 2001-12-17 PE PE2001001260A patent/PE20020718A1/es not_active Application Discontinuation
- 2001-12-17 TR TR2004/02758T patent/TR200402758T4/xx unknown
- 2001-12-17 CN CNB01821133XA patent/CN100475829C/zh not_active Expired - Fee Related
- 2001-12-17 DK DK05004699T patent/DK1593670T3/da active
- 2001-12-17 ES ES01991315T patent/ES2230385T3/es not_active Expired - Lifetime
- 2001-12-17 JP JP2002551983A patent/JP4351842B2/ja not_active Expired - Fee Related
- 2001-12-17 IL IL15577101A patent/IL155771A0/xx not_active IP Right Cessation
- 2001-12-17 SI SI200130760T patent/SI1593670T1/sl unknown
- 2001-12-17 DE DE60106489T patent/DE60106489T2/de not_active Expired - Lifetime
- 2001-12-18 TW TW090131349A patent/TWI316942B/zh not_active IP Right Cessation
- 2001-12-19 MY MYPI20015742A patent/MY129148A/en unknown
-
2003
- 2003-05-13 ZA ZA200303694A patent/ZA200303694B/en unknown
- 2003-06-19 NO NO20032806A patent/NO326981B1/no not_active IP Right Cessation
- 2003-06-19 MA MA27205A patent/MA26975A1/fr unknown
- 2003-06-19 EC EC2003004659A patent/ECSP034659A/es unknown
-
2004
- 2004-11-19 GE GEAP8505A patent/GEP20053548B/en unknown
-
2007
- 2007-10-08 CY CY20071101279T patent/CY1106912T1/el unknown
-
2008
- 2008-08-29 NO NO20083737A patent/NO20083737L/no not_active Application Discontinuation
-
2009
- 2009-03-25 JP JP2009075266A patent/JP2009132745A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035611A1 (es) | 2 -azetidinonas sustituidas con azucares, composicion farmaceutica, un kit, uso de dichos compuestos para la fabricacion de medicamentos utiles como agentes hipocolesterolemicos. | |
| ES2363941T3 (es) | Derivados de c-glucósido para el tratamiento de diabetes. | |
| RU2010145916A (ru) | Ингибитор pai-1 | |
| ES2649737T3 (es) | Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio | |
| RU2468029C2 (ru) | Ингибиторы hcv ns3 протеазы | |
| JP2006501181A5 (es) | ||
| RU2003134544A (ru) | Амиды антраниловой кислоты, способы их получения, их применение в качестве антиаритмических средств, а также содержащие их фармацевтические композиции | |
| HUP0300393A2 (hu) | C-aril glükozid SGLT2 inhibitorok és alkalmazásuk, valamint ezeket tartalmazó gyógyszerkészítmények | |
| RU2009106858A (ru) | Замещенные спирокетальные производные и их применение в качестве терапевтического средства при диабете | |
| AR033525A1 (es) | Arilmetilaminas sustituidas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento | |
| AR062793A1 (es) | Compuestos de azetidinona espirociclicos y metodos para su uso | |
| AR048377A1 (es) | Benzoimidazol-, benzotriazol- y benzoimidazolona - o- glucosidos sustituidos | |
| KR970705393A (ko) | 암 치료를 위한 화합물 및 방법(compounds and methods for the treatment of cancer) | |
| FR2805817B1 (fr) | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation | |
| RU2009102832A (ru) | С-фенил-1-тилоглюцитолы | |
| LV12211A (lv) | Homoeritromicina-a atvasinajumi | |
| EP1400529A4 (en) | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF | |
| AR063804A1 (es) | Compuestos de azoniabiciclo[2.2.2]octano | |
| EA200600694A1 (ru) | Дисульфидные, сульфидные, сульфоксидные и сульфоновые производные циклических сахаров и их применение | |
| TR200402454T4 (tr) | C-4 karbonat taksanlar. | |
| AR048808A1 (es) | Pirrolocarbazoles fusionados | |
| JPWO2019168999A5 (es) | ||
| UY28688A1 (es) | Derivados de amida | |
| ES2108240T3 (es) | Derivados de tiosemicarbazona de 2-formilpiridina, su preparacion y su uso como agentes antitumor. | |
| WO2011056744A4 (en) | IRE-1 α INHIBITORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |